Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SCN4A | P35499 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27386888 | 0.77 | KCNH2 (0.43) | APPMAOBCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10404570 | 0.77 | MAOB (0.42) | APPDRD4MAOBALDH3A1CYP1A2 | |
| SCHEMBL4174011 | 0.77 | MAOB (0.42) | APPDRD4MAOBCYP1A2CYP2C9 | |
| SCHEMBL794717 | 0.77 | DRD4 (0.43) | APPDRD4MAOBCYP1A2CYP2C9 | |
| SCHEMBL3453122 | 0.77 | CA12 (0.53) | APPMAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3184428 | 0.76 | AOC3 (0.54) | APPDRD4MAOBCYP2C9CYP2C19 | |
| SCHEMBL10565634 | 0.74 | AOC3 (0.42) | APPDRD4MAOBCYP1A2CYP2C9 | |
| SCHEMBL10348527 | 0.74 | MAOB (0.40) | APPDRD4MAOBCYP1A2CYP2C9 | |
| SCHEMBL11101055 | 0.74 | MAOB (0.40) | APPDRD4MAOBCYP1A2CYP2C9 | |
| SCHEMBL10905751 | 0.74 | MAOB (0.40) | APPDRD4MAOBCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189408-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. | 2024-06-13 | — | — | US | disclosed |
| EP-4381084-A1 | MRNAS ENCODING CHIMERIC METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | Modernatx, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| WO-2024084397-A1 | VACCINATION AGAINST PNEUMOCCOCAL AND COVID-19 INFECTIONS | PFIZER INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024057209-A1 | COAXIAL FLOW DEVICE FOR NANOPARTICLE PREPARATION AND MANUFACTURING EQUIPMENT INCLUDING SUCH DEVICE | PFIZER INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-4333879-A1 | VACCINATION AGAINST BACTERIAL AND BETACORONAVIRUS INFECTIONS | Pfizer Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4333880-A1 | IMMUNOGENIC COMPOSITION AGAINST INFLUENZA | Pfizer Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4314284-A1 | PURIFICATION AND RECYCLING OF MRNA NUCLEOTIDE CAPS | Modernatx, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024015366-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20240009291-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. | 2024-01-11 | — | — | US | disclosed |
| US-20230414516-A1 | ENHANCED FORMULATION STABILIZATION AND IMPROVED LYOPHILIZATION PROCESSES | BioNTech SE (DE) | 2023-12-28 | — | — | US | disclosed |
| EP-3394030-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | Modernatx, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| EP-3394093-A1 | METHODS OF USING OX40 LIGAND ENCODING POLYNUCLEOTIDES | Modernatx, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| EP-3350157-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | Modernatx, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017218704-A1 | STABILIZED FORMULATIONS OF LIPID NANOPARTICLES | MODERNATX, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| EP-3233132-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | Modernatx, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017112865-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112943-A1 | METHODS OF USING OX40 LIGAND ENCODING POLYNUCLEOTIDES | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017049245-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2016164762-A1 | POLYNUCLEOTIDES ENCODING LOW DENSITY LIPOPROTEIN RECEPTOR EGF-A AND INTRACELLULAR DOMAIN MUTANTS AND METHODS OF USING THE SAME | MODERNA THERAPEUTICS, INC. (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016100812-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414516-A1 | ENHANCED FORMULATION STABILIZATION AND IMPROVED LYOPHILIZATION PROCESSES | TREH, FUCA2, PDCD2L | APP 627/4885DRD4 493/4885MAOB 181/4885 |
| US-20240009291-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | MT-CO2, CYB5R3, COX5A | APP 2991/4885DRD4 1716/4885MAOB 1037/4885 |
| US-20240189408-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | MT-CO2, CYB5R3, COX5A | APP 2991/4885DRD4 1716/4885MAOB 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.